Meniere's Disease (MD) - Pipeline Insight, 2024

Meniere's Disease (MD) - Pipeline Insight, 2024

DelveInsight’s, “Meniere’s Disease - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Meniere’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Meniere’s Disease Understanding

Meniere’s Disease: Overview

Meniere’s disease is a chronic condition that affects the inner ear. The disease is characterized by episodic vertigo attacks, fluctuating hearing loss that becomes permanent over time, tinnitus, and a feeling of ear fullness. The cause of Meniere's disease is unknown. Meniere’s disease usually affects only one ear. Attacks of dizziness may come on suddenly or after a short period of tinnitus or muffled hearing. Some people will have single attacks of dizziness separated by long periods of time. People with Meniere's can experience a feeling of pressure in the ear, sudden dizzy spells, tinnitus, muffled hearing or hearing loss. The symptoms of Meniere’s disease are caused by the buildup of fluid in the compartments of the inner ear, called the labyrinth. Although Meniere's disease can affect people of any age, people in their 40s and 50s are much more likely to experience it. A series of diagnostic tests can be done to check the balance and hearing. These include: Audiometric exam, electronystagmogram, electrocochleography, and auditory brainstem response test among others. No cure exists for Meniere's disease. A number of treatments can help reduce the severity and frequency of vertigo episodes.

""Meniere’s Disease - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Meniere’s Disease pipeline landscape is provided which includes the disease overview and Meniere’s Disease treatment guidelines. The assessment part of the report embraces, in depth Meniere’s Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Meniere’s Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Meniere’s Disease R&D. The therapies under development are focused on novel approaches to treat/improve Meniere’s Disease.

Meniere’s Disease Emerging Drugs Chapters

This segment of the Meniere’s Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Meniere’s Disease Emerging Drugs

• OTIVIDEX: Otonomy

OTIVIDEX is a sustained-exposure formulation of the steroid dexamethasone. The drug is in clinical development for the treatment of Meniere’s disease. OTIVIDEX has been granted Fast Track designation for Meniere’s disease by the FDA.

• SPI-1005: Sound Pharmaceuticals

SPI-1005 is an investigational new drug that contains ebselen, a novel small molecule that mimics and induces the activity of Glutathione Peroxidase (GPx) in the inner ear, retina, brain, lung, and kidney. SPI-1005 represents a novel class of anti-inflammatory and is under clinical investigation in several neurotologic diseases where GPx activity is reduced including sensorineural hearing loss, tinnitus, ototoxicity, Meniere's disease, and in neuropsychiatric disease including bipolar mania and treatment-resistant depression. SPI-1005 is entering pivotal Phase 3 trials for the treatment of Meniere's disease and is currently in a Phase 2b study involving Cystic Fibrosis patients with acute respiratory infections receiving IV antibiotics.

Further product details are provided in the report……..

Meniere’s Disease: Therapeutic Assessment

This segment of the report provides insights about the different Meniere’s Disease drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Meniere’s Disease

There are approx. 10+ key companies which are developing the therapies for Meniere’s Disease. The companies which have their Meniere’s Disease drug candidates in the most advanced stage, i.e. Phase III include, Sound Pharmaceuticals.

• Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Meniere’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Meniere’s Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Meniere’s Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Meniere’s Disease drugs.

Meniere’s Disease Report Insights

• Meniere’s Disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Meniere’s Disease Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Meniere’s Disease drugs?
• How many Meniere’s Disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Meniere’s Disease?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Meniere’s Disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Meniere’s Disease and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Otonomy
• Synphora
• Sound Pharmaceuticals
• Auris Medical
• Apsen Farmaceutica
• Orbis Biosciences
• Quark Pharmaceuticals

Key Products

• OTIVIDEX
• Latanoprost intratympanic
• SPI-1005
• Betahistine intranasal
• APSLXR
• ORB 202
• QPI-1017